We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Pen-Like Device for Real Time Tissue Analysis to Revolutionize Surgical Pathology

By LabMedica International staff writers
Posted on 04 May 2023
Print article
Image: The non-invasive pen-like device enables painless tissue analysis (Photo courtesy of MS Pen)
Image: The non-invasive pen-like device enables painless tissue analysis (Photo courtesy of MS Pen)

For over a century, cancer tissue analysis has depended on long-established workflows, with traditional histopathology results typically taking 40 minutes or more. In this process, tissue is biopsied, sent to a lab, frozen, sliced, stained, and examined by a pathologist under a microscope. While awaiting results, the patient remains under anesthesia, increasing their risk of infection and incurring additional costs for both the patient and hospital. Now, a groundbreaking device incorporating cutting-edge mass spectrometry and artificial intelligence (AI) can identify cancerous tissue—in vivo and ex vivo—within just 10 seconds, empowering surgeons, oncologists, and healthcare providers with real-time decision-making capabilities.

The MasSpec Pen System from MS Pen Technologies (Houston, TX, USA) is a proprietary, user-friendly, disposable, and biocompatible device that facilitates rapid tissue analysis. This non-invasive pen-like instrument grants medical professionals access to sophisticated technology that was previously available only to specialists. The MasSpec Pen System ensures fast, precise and highly accurate tissue identification, both in vivo and ex vivo. The more cancer is removed, the less likely tumors will recur and the less likely patients will need adjuvant treatments.

The MasSpec Pen System requires only a small amount of water and three seconds of gentle contact, eliminating the need to destroy or remove healthy tissue. This results in improved precision, recovery periods, and outcomes. Probes from the disposable MasSpec pen connect directly to the mass spectrometer's console, which analyzes the droplet to generate a unique molecular fingerprint of the sample. Advanced data analytics and AI transform complex metabolic data into straightforward, actionable information. Predictive statistical models built from molecular data distinguish between normal and cancerous tissues. In 10 seconds or less, the software provides easily interpretable diagnostic results in real time.

With the MasSpec Pen System, medical professionals can characterize tissues without leaving the operating room or extracting tissue from the patient. This portable, battery-operated machine can be relocated as needed—whether to a patient room or just inches from the operating table. Due to its quick and non-invasive nature, the process can be repeated multiple times if suspicious tissue remains. By eliminating the need for repeated invasive pathology results, the MasSpec Pen System significantly reduces procedure times, decreases extended anesthesia use, lowers the risk of infection, and minimizes financial burdens for both patients and hospital systems.

Related Links:
MS Pen Technologies 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The QIAstat-Dx Respiratory Panel Plus has received U.S. FDA clearance (Photo courtesy of QIAGEN)

New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results

Respiratory tract infections are a major reason for emergency department visits and hospitalizations. According to the CDC, the U.S. sees up to 41 million influenza cases annually, resulting in several... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more